TABLE 2.

Spearman Correlation Coefficients Between ZBPI Worst Pain Score AUC and Each Corresponding SF-36 Domain and EQ-5D Utility Score AUC During First 30 Days of Herpes Zoster Episode

		Correlation coefficient/P/(N)
	Domain	ZOE-50/70	ZOE-HSCT
SF-36	PF	−0.485/<0.0001/N=499	−0.425/<0.0001/N=152
	RP	−0.571/<0.0001/N=499	−0.491/<0.0001/N=151
	BP	−0.785/<0.0001/N=498	−0.757/<0.0001/N=152
	GH	−0.372/<0.0001/N=499	−0.319/<0.0001/N=152
	VT	−0.536/<0.0001/N=499	−0.428/<0.0001/N=151
	SF	−0.596/<0.0001/N=498	−0.421/<0.0001/N=152
	MH	−0.483/<0.0001/N=499	−0.357/<0.0001/N=151
	RE	−0.510/<0.0001/N=499	−0.374/<0.0001/N=151
EQ-5D	Utility	−0.701/<0.0001/N=498	−0.615/<0.0001/N=151
	VAS	−0.557/<0.0001/N=498	−0.486/<0.0001/N=151

ZOE-50/70=Placebo participants from the ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) studies who had an herpes zoster episode.

ZOE-HSCT=Placebo participants from the ZOE-HSCT study (NCT01610414) who had an herpes zoster episode.

N=Number of participants with a nonmissing ZBPI AUC and domain AUC during the first 30 days of the herpes zoster episode.

AUC indicates area under curve; BP, Bodily Pain; EQ-5D, EuroQoL EQ-5D; GH, General Health; HSCT, hematopoietic stem cell transplantation; MH, Mental Health; PF, Physical Functioning; RE, Role Emotional; RP, Role Physical; SF, Social Functioning; SF-36, Short Form Health Survey 36; Utility, Utility Score; VAS, Visual Analog Scale; VT, Vitality; ZBPI, Zoster Brief Pain Inventory.